Gene therapy for diabetic neuropathy using an hgf isoform

ABSTRACT

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/355,792, filed May 30, 2014, which is a National Stage of International Application No. PCT/KR2012/002224, filed Mar. 27, 2012; which claims the benefit of KR Application No. 10-2011-0113786, filed Nov. 3, 2011, each of which is incorporated in its entirety by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 30, 2018, is named 37210US_CRF_sequencelisting.txt, and is 77,473 bytes in size.

TECHNICAL FIELD

The present invention relates to a composition for the prevention or treatment of diabetic neuropathy, comprising, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

BACKGROUND ART

Hepatocyte growth factor (HGF) is a heparin-binding glycoprotein also known as scatter factor or hepatopoietin-A. HGF that has been first identified as a potent hepatotropic growth factor (Nakamura et al., Nature 342:440 (1989)) is a mesenchymal-derived heparin-binding protein having multiple biological effects such as mitogenesis, motogenesis, and morphogenesis of various types of cells. A gene encoding HGF is located at chromosome 7q21.1, and involves 18 exons and 17 introns (Seki T., et al., Gene 102:213-219 (1991)).

A transcript of about 6 kb is transcribed from the HGF gene, and then a full-length polypeptide HGF precursor (f1HGF) composed of 728 amino acids is synthesized therefrom, wherein the f1HGF includes the following domains: N-terminal hairpin loop-kringle 1-kringle 2-kringle 3-kringle 4-inactivated serine protease. Simultaneously, several other HGF polypeptide isoforms are synthesized by an alternative splicing of the HGF gene. Known isoforms include deleted variant HGF (deletion of five amino acids from kringle 1 of the full-length HGF), NK1 (N-terminal hairpin loop-kringle 1), NK2 (N-terminal hairpin loop-kringle 1-kringle 2), and NK4 (N-terminal hairpin loop-kringle 1-kringle 2-kringle 3-kringle 4). In addition, there are allelic variants of each isoform. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a pre-activated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low-molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting of 723 amino acids is a polypeptide with deletion of five amino acids in the first kringle domain of the alpha chain, i.e., F, L, P, S and S, due to alternative splicing between exon 4 and exon 5.

In vivo, two isoforms of HGF (f1HGF having 728 amino acids and dHGF having 723 amino acids) are generated through alternative splicing between exon 4 and exon 5. Both of f1HGF and dHGF are the same in view of several biological functions, but are different from each other in terms of immunological characteristics and several biological characteristics. For example, f1HGF exhibits about 20-fold, 10-fold and 2-fold higher activities than dHGF in terms of promoting DNA synthesis in human umbilical cord venous endothelial cell, arterial smooth muscle cell, and NSF-60 (murine myeloblast cell), respectively. dHGF exhibits about 3-fold and 2-fold higher activities than f1HGF in terms of promoting DNA synthesis of LLC-PK1 (pig kidney epithelial cells), and OK (American opossum kidney epithelial cells), and mouse interstitial cells, respectively. In addition, f1HGF exhibits 70-fold higher solubility in PBS than dHGF. Several anti-dHGF monoclonal antibodies recognize only dHGF and f1HGF or a reduced form of dHGF, which implies that the three-dimensional structures of HGF and dHGF are different.

HGF has been shown to stimulate angiogenesis by regulating the growth of endothelial cells and migration of vascular smooth muscle cells. Due its angiogenic activity, HGF is regarded as one of the promising candidates in therapeutic angiogenesis. “Therapeutic angiogenesis” means an intervention that utilizes angiogenic factors as recombinant proteins or genes, for the treatment of ischemic diseases, such as coronary artery disease (CAD) or peripheral artery disease (PAD). HGF has been also known to stimulate not only the growth but also the migration of endothelial cells (Bussolino et al., J Cell Biol. 119:629 (1992); Nakamura et al., J Hypertens 14:1067 (1996)), and has been tested for its role as a re-endothelialization stimulating agent (Yasuda et al., Circulation 101:2546 (2000); Hayashi et al., Gene Ther 7:1664 (2000)). All of the studies on HGF gene therapy described above have been conducted by using f1HGF cDNA encoding 728 amino acids, but not dHGF cDNA encoding 723 amino acids.

Diabetic Neuropathies are serious and dangerous diabetic complications, and, in many cases, they lead to simultaneous occurrence of several types of neuropathies. Diabetic neuropathies are largely classified into polyneuropathy and focal neuropathy. The polyneuropathy includes hyperglycemic neuropathy, distal symmetric polyneuropathy, autonomic neuropathy, acute sensory neuropathy, acute painful sensory neuropathy, chronic sensorimotor neuropathy, and the like. The focal neuropathy includes cranial neuropathy, truncal neuropathy, limb neuropathy, thoracolumbar radiculoneuropathy, lumbosacral radiculoplexus neuropathy, and the like (Andrew J. M. et al., Diabetescare 28:956-962 (2005); J Gareth Llewelyn et al., J Neurol Neurosurg Psychiatry 74:15-19 (2003)). Diabetic Neuropathy has severe pain and loss of mobility as its representative symptoms. According to statistics from the U.S., 60 to 70% of people with diabetes have been known to have diabetic neuropathy (American Diabetes Association (ADA), National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)), and 3.9 million or more diabetic patients aged 40 or over have been known to have diabetic neuropathy. The economic cost of these is estimated to be up to $13.7 billion per year, and this cost is expected to increase continuously.

Currently permitted drugs for diabetic neuropathy are only Lyrica® of Pfizer and Cymbalta® of Eli Lilly. However, these two drugs are merely a kind of painkiller alleviating pains shown in diabetic neuropathy, and may not delay the progress of disease or fundamentally ameliorate symptoms. Besides this medicine treatment, allopathy for pain relief, motor function improvement, and mental stress reduction are being used. There is no fundamental treatment at present, and the control of diabetes through dietary control is the only way to minimize the occurrence of diabetic neuropathy. Therefore, new novel of therapeutic agents capable of suppressing or ameliorating the progress of diabetic neuropathy need to be developed.

Throughout this application, several patents and publications are referenced and citations are provided in parentheses. The disclosure of these patents and publications is incorporated into this application in order to more fully describe this invention and the state of the art to which this invention pertains.

DETAILED DESCRIPTION OF THE INVENTION Technical Problem

The present inventors have endeavored to develop therapeutic agents capable of effectively treating diabetic neuropathy. As a result, the present inventors have found that the expression of different types of isoforms of hepatocyte growth factor (HGF) can effectively treat diabetic neuropathy, and then completed the present invention.

Therefore, the present invention has been made in view of the above-mentioned problems, and an aspect of the present invention is to provide a pharmaceutical composition for preventing or treating diabetic neuropathy.

Another aspect of the present invention is to provide a method for preventing or treating diabetic neuropathy.

Other purposes and advantages of the present disclosure will become clarified by the following detailed description of the invention, claims, and drawings.

Technical Solution

In accordance with an aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, the composition including, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

In accordance with another aspect of the present invention, there is provided a method for the prevention or treatment of diabetic neuropathy, the method including administering to a mammal a composition containing, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

The present inventors have endeavored to develop therapeutic agents capable of effectively treating diabetic neuropathy. As a result, the present inventors have found that the expression of different types of isoforms of hepatocyte growth factor (HGF) can effectively treat diabetic neuropathy.

The present invention is mainly characterized in that different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide sequence encoding the isoforms are used to prevent and treat diabetic neuropathy.

Treatment strategy of the present invention may be largely classified into two types: protein therapy and gene therapy.

According to the protein therapeutic agent strategy of the present invention, two or more types of isomeric proteins of HGF are used. The two or more types of isomeric proteins of HGF may be provided by one polypeptide or separate polypeptides. Preferably, the two or more types of isomeric proteins of HGF are provided by one polypeptide.

According to the gene therapeutic agent strategy of the present invention, at least one nucleotide sequence encoding two or more types of isomers of HGF is used. A polynucleotide sequence encoding two or more types of isomers of HGF may be provided by one polynucleotide or separate polynucleotides. Preferably, the polynucleotide sequence encoding two or more types of isomers of HGF is provided by one polynucleotide.

Hereinafter, the present invention will be described in detail.

As used herein, the term “isoform of HGF” refers to an HGF polypeptide having an amino acid sequence that is at least 80% identical to a naturally occurring HGF amino acid sequence in an animal, including all allelic variants. For example, the isoform of HGF has a meaning including all of normal forms or wild types of HGF and various variants of HGF (e.g., splice variants and deletion variants).

According to a preferable embodiment of the present invention, the different types of isoforms of HGF include two or more isoforms selected from the group consisting of full-length HGF, (f1HGF), deleted variant HGF (dHGF), NK1, NK2, and NK4.

According to a more preferable embodiment of the present invention, the different types of isoforms of HGF of the present invention include f1HGF and dHGF.

As used herein, the term “f1HGF” refers to a sequence of amino acids 1-728 of the HGF protein from an animal, preferably a mammal, and more preferably a human. Human f1HGF includes the amino acid sequence of SEQ ID NO: 1.

As used herein, the term “dHGF” refers to the deleted variant of the HGF protein produced by alternative splicing of the HGF gene from an animal, and preferably a mammal. More preferably, the term “dHGF” refers to human HGF with deletion of five amino acids (F, L, P, S, and S) in the first kringle domain of the alpha chain from the full length HGF sequence, consisting of 723 amino acids. The human dHGF includes the amino acid sequence of SEQ ID NO: 2.

As used herein, the term “NK1” refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop and the kringle 1 domain. Human NK1 includes the amino acid sequence of SEQ ID NO: 3.

As used herein, the term “NK2” refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop, the kringle 1 domain, and the kringle 2 domain. Human NK2 includes the amino acid sequence of SEQ ID NO: 4.

As used herein, the term “NK4” refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop, the kringle 1 domain, the kringle 2 domain, the kringle 3 domain, and the kringle 4 domain. Human NK4 includes the amino acid sequence of SEQ ID NO: 5.

According to a preferable embodiment of the present invention, the different types of isoforms of HGF may be encoded by separate polynucleotides or a single polynucleotide. Herein, the different types of isoforms of HGF may include two or more polynucleotides when being encoded by separate polynucleotides, and the different types of isoforms of HGF may include at least one polynucleotide when being encoded by a single polynucleotide.

The polynucleotide of the present invention may be operatively linked to at least one regulatory sequence (e.g., a promoter or an enhancer) regulating expression of the isoforms of HGF.

When the two or more types of isoforms of HGF are encoded by separate polynucleotides, an expression cassette may be constructed in two manners. According to a first manner, the expression cassette is constructed by linking an expression regulatory sequence to a coding sequence (CDS) of each isoform. According to a second manner, the expression cassette is constructed by using an internal ribosomal entry site (IRES), like “expression regulatory sequence-CDS of first isomer-IRES -CDS of second isomer-transcription termination sequence”. The IRES allows the gene translation to start at the IRES sequence, thereby resulting in the expression of two genes of interest in the same construct.

When two or more types of isoforms of HGF are encoded by a single polynucleotide, the polynucleotide encoding all the two or more types of isoforms of HGF is operatively linked to a single expression regulatory sequence.

Herein, the isoforms of HGF may be encoded by a hybrid HGF gene simultaneously expressing two or more different types of isoforms of HGF, e.g., f1HGF and dHGF.

According to a preferable embodiment of the present invention, the hybrid HGF gene includes cDNA corresponding exon 1-18 of human HGF and intron 4 of a human HGF gene or its fragment, which is inserted between exon 4 and exon 5 of the cDNA.

According to a more preferable embodiment of the present invention, the hybrid HGF gene includes a nucleotide sequence selected from the group consisting of SEQ ID NO: 7 to SEQ ID NO: 14.

The hybrid HGF gene including intron 4 is 7112 bp long and includes the nucleotide sequence of SEQ ID NO: 7. The hybrid HGF gene may selectively include a fragment of intron 4 between exon 4 and exon 5 of HGF cDNA.

According to a preferable embodiment of the present invention, the sequence additionally inserted between exon 4 and exon 5 includes: intron 4 of the human HGF gene, nucleotides 392-2247, nucleotides 392-727, nucleotides 2229-5471, nucleotides 5117-5471, nucleotides 3167-5471, nucleotides 4167-5471, or a combination thereof, of SEQ ID NO: 7.

More preferably, the sequence additionally inserted between exon 4 and exon 5 of the therapeutic nucleotide sequence used in the present invention is (i) nucleotides 392-2247 and nucleotides 2229-5471 of SEQ ID NO: 7; (ii) nucleotides 392-2247 and nucleotides 5117-5471 of SEQ ID NO: 7; (iii) nucleotides 392-2247 and nucleotides 3167-5471 of SEQ ID NO: 7; (iv) nucleotides 392-2247 and nucleotides 4167-5471 of SEQ ID NO: 7; (v) nucleotides 392-727 and nucleotides 2229-5471 of SEQ ID NO: 7; (vi) nucleotides 392-727 and nucleotides 5117-5471 of SEQ ID NO: 7; (vii) nucleotides 392-727 and nucleotides 3167-5471 of SEQ ID NO: 7; or (viii) nucleotides 392-727 and nucleotides 4167-5471 of SEQ ID NO: 7.

The therapeutic nucleotide sequence of the present invention according to the sequence additionally inserted between exon 4 and exon 5 is summarized as below. (i) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 2297-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (ii) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 5117-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (iii) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 3167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (iv) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 4167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (v) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 2229-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (vi) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 5117-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (vii) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 3167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); and (viii) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 4167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18).

Herein, the hybrid HGF gene including a fragment of intron 4 is named “HGF-X”. The HGF-X includes HGF-X2, HGF-X3, HGF-X4, HGF-X5, HGF-X6, HGF-X7, and HGF-X8 having nucleotide sequences of SEQ ID NO: 8 to SEQ ID NO: 14, respectively.

The amino acid sequences and nucleotide sequences of HGF isoforms used in this invention may include amino acid sequences and nucleotide sequences substantially identical sequences to sequences of the wild type human HGF isoforms. The substantial identity includes sequences with at least 80% identity, more preferably at least 90% identity and most preferably at least 95% identity as measured using one of the sequence comparison algorithms where the amino acid sequence or nucleotide sequence of the wild type human HGF isoform is aligned with a sequence in the maximal manner. Methods of alignment of sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2: 482 (1981); Needleman and Wunsch, J. Mol. Bio. 48: 443 (1970); Pearson and Lipman, Methods in Mol. Biol. 24: 307-31 (1988); Higgins and Sharp, Gene 73: 237-44 (1988); Higgins and Sharp, CABIOS 5: 151-3 (1989) Corpet et al., Nuc. Acids Res. 16: 10881-90 (1988); Huang et al., Comp. Appl. BioSci. 8: 155-65 (1992); and Pearson et al., Meth. Mol. Biol. 24: 307-31 (1994). The NCBI Basic Local Alignment Search Tool (BLAST) [Altschul et al., J. Mol. Biol. 215: 403-10 (1990)] is available from several sources, including the National Center for Biological Information (NBCl, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blasm, blastx, tblastn and tblastx. BLAST can be accessed at http://www.ncbi.nlm.nih.gov/BLAST/. A description of how to determine sequence identity using this program is available at http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html.

As used herein, the term “prevention” refers to all the acts of suppressing diabetic neuropathy or delaying the progress of diabetic neuropathy through administration of the composition of the present invention.

As used herein, the term “treatment” refers to (a) suppression of the development of diabetic neuropathy; (b) alleviation of diabetic neuropathy; and (c) removal of diabetic neuropathy.

About 15% of persons with diabetes show signs and symptoms of diabetic neuropathy, and among them, about 50% are found to have the traumatic damage of peripheral nerves on the electroneurography. Diabetic neuropathy is common among patients aged 50 or over, and various clinical subclass types are present. Pain is one of the common symptoms of diabetic neuropathy, and the frequency of pain varies depending on the patient.

According a preferable embodiment of the present invention, the composition of the present invention can prevent or treat diabetic neuropathy through the growth of neuronal cells or the suppression of neuronal cell death.

According to the present invention, when the PC12 neuronal cell line was treated with the isoforms f1HGF and dHGF, the cell growth effect was 50% and 70% higher than those in control groups treated with f1HGF and dHGF alone, respectively. In addition, when SH-SY5Y neuroblasts were treated with f1HGF and dHGF, the cell growth effect was 25% and 80% higher than those in control groups treated with the isoforms f1HGF and dHGF alone, respectively.

According to the present invention, when the PC12 neuronal cell line treated with high-concentration glucose was treated with the isoforms f1HGF and dHGF, the apoptosis of neuronal cells by glucose was reduced by about 2 fold, and the effect of inhibiting apoptosis of neuronal cells was about 1.5-fold higher than that in the control group treated with f1HGF.

According to the present invention, the safety of the isoforms of HGF and the pain reduction effects of the isoforms were confirmed through clinical trials in which the patients with diabetic neuropathy were injected with a polynucleotide expressing the isoforms f1HGF and dHGF. Therefore, the composition of the present invention is useful to the prevention and the treatment of diabetic neuropathy.

According to a preferable embodiment of the present invention, diabetic neuropathies of the present invention are largely classified into polyneuropathy and focal neuropathy.

According to a preferable embodiment of the present invention, the polyneuropathy of the present invention includes one or more diseases selected from the group consisting of hyperglycemic neuropathy, distal symmetric polyneuropathy, autonomic neuropathy, acute sensory neuropathy, acute painful sensory neuropathy, and chronic sensorimotor neuropathy, and the focal neuropathy of the present invention includes one or more diseases selected from the group consisting of cranial neuropathy, truncal neuropathy, limb neuropathy, thoracolumbar radiculoneuropathy, and lumbosacral radiculoplexus neuropathy. However, they are not limited thereto.

The composition of the present invention may be applied in vivo through various delivery methods conventionally known in the field of gene therapy.

According to a preferable embodiment of the present invention, the polynucleotide of the present invention is naked DNA or contained in a gene carrier. Examples of the gene carrier include plasmid, vector, and viral vector.

(i) Plasmid (Vector)

Plasmids (vectors) may be used as a gene carrier for the polynucleotide of the present invention.

It is preferred that the polynucleotide in vectors is contained in a suitable expression construct. According the expression construct, it is preferred that the polynucleotide is operatively linked to a promoter. The term “operatively linked” refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.

According to the present invention, the promoter linked to the polynucleotide is operable in, preferably, animal, more preferably, mammalian cells, to control transcription of the polynucleotide, including the promoters derived from the genome of mammalian cells or from mammalian viruses, for example, CMV (cytomegalovirus) promoter, the adenovirus late promoter, the vaccinia virus 7.5K promoter, SV40 promoter, HSV tk promoter, RSV promoter, EF1 alpha promoter, metallothionein promoter, beta-actin promoter, human IL-gene promoter, human IFN gene promoter, human IL-4 gene promoter, human lymphotoxin gene promoter and human GM-CSF gene promoter, but not limited to. More preferably, the promoter useful in this invention is a promoter derived from the IE (immediately early) gene of human CMV (hCMV) or EF1 alpha promoter, most preferably hCMV IE gene-derived promoter/enhancer and 5′-UTR (untranslated region) comprising the overall sequence of exon 1 and exon 2 sequence spanning a sequence immeidately before the ATG start codon.

The expression cassette used in this invention may comprise a polyadenylation sequence, for example, including bovine growth hormone terminator (Gimmi, E. R., et al., Nucleic Acids Res. 17:6983-6998 (1989)), SV40-derived polyadenylation sequence (Schek, N, et al., Mol. Cell Biol. 12:5386-5393 (1992)), HIV-1 polyA (Klasens, B. I. F., et al., Nucleic Acids Res. 26:1870-1876 (1998)), β-globin polyA (Gil, A., et al, Cell 49:399-406 (1987)), HSV TK polyA (Cole, C. N. and T. P. Stacy, Mol. Cell. Biol. 5:2104-2113 (1985)) or polyoma virus polyA (Batt, D. B and G. G. Carmichael, Mol. Cell. Biol. 15:4783-4790 (1995)), but not limited to.

According to a preferable embodiment, the gene carrier for the polynucleotide includes pCK, pCP, pVAX1 and pCY vecors, more preferably pCK vector of which details are found in WO 2000/040737.

(ii) Retrovirus

Retroviruses capable of carrying relatively large exogenous genes have been used as viral gene delivery vectors in the senses that they integrate their genome into a host genome and have broad host spectrum.

In order to construct a retroviral vector, the polynucleotide of the invention is inserted into the viral genome in the place of certain viral sequences to produce a replication-defective virus. To produce virions, a packaging cell line containing the gag, pol and env genes but without the LTR (long terminal repeat) and Ψ components is constructed (Mann et al., Cell, 33:153-159(1983)). When a recombinant plasmid containing the polynucleotide of the invention, LTR and Ψ is introduced into this cell line, the Ψ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubinstein “Retroviral vectors,” In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513(1988)). The media containing the recombinant retroviruses is then collected, optionally concentrated and used for gene delivery.

A successful gene transfer using the second-generation retroviral vector has been reported. Kasahara et al. (Science, 266:1373-1376(1994)) prepared variants of moloney murine leukemia virus in which the EPO (erythropoietin) sequence is inserted in the place of the envelope region, consequently, producing chimeric proteins having novel binding properties. Likely, the present gene delivery system can be constructed in accordance with the construction strategies for the second-generation retroviral vector.

(iii) Adenovirus

Adenovirus has been usually employed as a gene delivery system because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range, and high infectivity. Both ends of the viral genome contains 100-200 bp ITRs (inverted terminal repeats), which are cis elements necessary for viral DNA replication and packaging. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication.

Of adenoviral vectors developed so far, the replication incompetent adenovirus having the deleted E1 region is usually used. The deleted E3 region in adenoviral vectors may provide an insertion site for transgenes (Thimmappaya, B. et al., Cell, 31:543-551(1982); and Riordan, J. R. et al., Science, 245:1066-1073(1989)). Therefore, it is preferred that the decorin-encoding nucleotide sequence is inserted into either the deleted E1 region (E1A region and/or E1B region, preferably, E1B region) or the deleted E3 region. The polynucleotide of the invention may be inserted into the deleted E4 region. The term “deletion” with reference to viral genome sequences encompasses whole deletion and partial deletion as well. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA (Ghosh-Choudhury et al., EMBO J., 6:1733-1739(1987)). In this regard, the foreign sequences described above inserted into adenovirus may be further inserted into adenoviral wild-type genome.

The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the most preferred starting material for constructing the adenoviral gene delivery system of this invention. A great deal of biochemical and genetic information about adenovirus type 5 is known. The foreign genes delivered by the adenoviral gene delivery system are episomal, and therefore, have low genotoxicity to host cells. Therefore, gene therapy using the adenoviral gene delivery system of this invention may be considerably safe.

(iv) AAV Vectors

Adeno-associated viruses are capable of infecting non-dividing cells and various types of cells, making them useful in constructing the gene delivery system of this invention. The detailed descriptions for use and preparation of AAV vector are found in U.S. Pat. Nos. 5,139,941 and 4,797,368.

Research results for AAV as gene delivery systems are disclosed in LaFace et al, Viology, 162:483486(1988), Zhou et al., Exp. Hematol. (NY), 21:928-933(1993), Walsh et al, J. Clin. Invest., 94:1440-1448(1994) and Flotte et al., Gene Therapy, 2:29-37(1995). Recently, an AAV vector has been approved for Phase I human trials for the treatment of cystic fibrosis.

Typically, a recombinant AAV virus is made by cotransfecting a plasmid containing the gene of interest (i.e., decorin gene and nucleotide sequence of interest to be delivered) flanked by the two AAV terminal repeats (McLaughlin et al., 1988; Samulski et al., 1989) and an expression plasmid containing the wild type AAV coding sequences without the terminal repeats (McCarty et al., J. Virol., 65:2936-2945(1991)).

(v) Other Viral Vectors

Other viral vectors may be employed as a gene delivery system in the present invention. Vectors derived from viruses such as vaccinia virus (Puhlmann M. et al., Human Gene Therapy 10:649-657(1999); Ridgeway, “Mammalian expression vectors,” In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt, eds. Stoneham: Butterworth, 467-492(1988); Baichwal and Sugden, “Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes,” In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148(1986) and Coupar et al., Gene, 68:1-10(1988)), lentivirus (Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999)) and herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415(1995)) may be used in the present delivery systems for transferring both the polynucleotide of the invention into cells.

(vi) Liposomes

Liposomes are formed spontaneously when phospholipids are suspended in an excess of aqueous medium. Liposome-mediated nucleic acid delivery has been very successful as described in Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190(1982) and Nicolau et al., Methods Enzymol., 149:157-176(1987). Example of commercially accessible reagents for transfecting animal cells using liposomes includes Lipofectamine (Gibco BRL). Liposomes entrapping polynucleotide of the invention interact with cells by mechanism such as endocytosis, adsorption and fusion and then transfer the sequences into cells.

Where the gene delivery system is a naked recombinant DNA molecule or plasmid, the polynucleotide sequence of the invention is introduced into cells by microinjection (Capecchi, M. R., Cell, 22:479(1980) and Harland and Weintraub, J. Cell Biol. 101:1094-1099(1985)), calcium phosphate co-precipitation (Graham, F. L. et al., Virology, 52:456(1973) and Chen and Okayama, Mol. Cell. Biol. 7:2745-2752(1987)), electroporation (Neumann, E. et al., EMBO J., 1:841(1982) and Tur-Kaspa et al., Mol. Cell Biol., 6:716-718(1986)), liposome-mediated transfection (Wong, T. K. et al., Gene, 10:87(1980) and Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190(1982); and Nicolau et al., Methods Enzymol., 149:157-176(1987)), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5:1188-1190(1985)), and particle bombardment (Yang et al., Proc. Natl. Acad. Sci., 87:9568-9572(1990)).

When the polynucleotide sequence of the present invention is constructed based on the viral vector, the polynucleotide sequence may be delivered into cells by various viral infection methods known in the art. The infection of host cells using viral vectors are described in the above-mentioned cited documents.

The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.

The pharmaceutically acceptable carrier may be conventional one for formulation, including lactose, dextrose, sucrose, sorbitol, mannitol, starch, rubber arable, potassium phosphate, arginate, gelatin, potassium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oils, but not limited to. The pharmaceutical composition according to the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, and a preservative. Details of suitable pharmaceutically acceptable carriers and formulations can be found in Remington's Pharmaceutical Sciences (19th ed., 1995), which is incorporated herein by reference.

Preferably, the pharmaceutical composition of this invention may be administered parenterally. For non-oral administration, intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, or local injection may be employed. For example, the pharmaceutical composition may be injected by retrograde intravenous injection.

Preferably, the pharmaceutical composition of the present invention may be administered into the muscle, and more preferably into the calf muscle.

A suitable dosage amount of the pharmaceutical composition of the present invention may vary depending on pharmaceutical formulation methods, administration methods, the patient's age, body weight, sex, pathogenic state, diet, administration time, administration route, an excretion rate and sensitivity for a used pharmaceutical composition, and physicians of ordinary skill in the art can determine an effective amount of the pharmaceutical composition for desired treatment.

According to a preferable embodiment of the present invention, the isoforms of HGF of the present invention are administered at a dose of 1 μg to 100 mg for each, and the polynucleotide encoding the isoforms is administered at a dose of 1 μg to 40 mg. When the isoforms of HGF or the polynucleotide encoding the isoforms is repeatedly administered once or more, the dose may be equal or different for each administration.

According to the conventional techniques known to those skilled in the art, the pharmaceutical composition may be formulated with pharmaceutically acceptable carrier and/or vehicle as described above, finally providing several forms a unit dose form and a multi-dose form. Non-limiting examples of the formulations include, but not limited to, a solution, a suspension or an emulsion in oil or aqueous medium, an extract, an elixir, a powder, a granule, a tablet and a capsule, and may further comprise a dispersion agent or a stabilizer.

Advantageous Effects

Features and advantages of the present invention are summarized as follows:

(a) The pharmaceutical composition of the present invention for preventing or treating diabetic neuropathy contains, as active ingredients, different types of isoforms of HGF or at least one polynucleotide encoding the isoforms.

(b) The present invention first established that the use of different types of isoforms of HGF or at least one polynucleotide expressing the isomers can treat diabetic neuropathy more effectively than the use of the full-length HGF.

(c) According to the present invention, diabetic neuropathy can be treated very effectively.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram showing a procedure for constructing pVAX1-cHGF.

FIG. 2 is a diagram showing a procedure for constructing pVAX1-HGF-X7.

FIG. 3 is a diagram showing a procedure for constructing pCY-cHGF and pCY-dHGF.

FIG. 4 is a diagram showing a procedure for constructing pCY-HGF-X3, pCY-HGF-X4, pCY-HGF-X7, and pCY-HGF-X8.

FIG. 5 is a diagram showing a procedure for constructing pCY-HGF-X2 and pCY-HGF-X6.

FIG. 6 is a diagram showing a procedure for constructing pCY-HGF-X5.

FIG. 7 shows results of RNA expression of respective isoforms of HGF.

FIG. 8 shows results of protein expression of respective isoforms of HGF.

FIG. 9 shows effects of isoforms of HGF on the growth of PC12 cells.

FIG. 10 shows an effect of pCK-HGF-X7 on the growth of PC12 cells.

FIG. 11 shows an effect of pCK-HGF-X7 on the growth of SH-SY5Y cells.

FIG. 12 shows an effect of pCK-HGF-X7 on PC12 cells that are growth-inhibited by high-concentration glucose.

FIG. 13 shows an effect of pCK-HGF-X7 on apoptosis of PC12 cells, induced by high-concentration glucose.

FIG. 14 is a diagram illustrating the visual analogue scale (VAS) estimation.

FIG. 15 shows results of pharmacodynamics of pCK-HGF-X7.

FIG. 16 shows results of efficacy of pCK-HGF-X7.

FIG. 17 shows results of efficacy of pCK-HGF-X7 in a first dose group (4 mg).

FIG. 18 shows results of efficacy of pCK-HGF-X7 in a second dose group (8 mg).

FIG. 19 shows results of efficacy of pCK-HGF-X7 in a third dose group (16 mg).

FIG. 20 shows the comparison of VAS among three dose groups (4 mg, 8 mg, and 16 mg).

MODE FOR CARRYING OUT THE INVENTION

The present invention will now be described in further detail by examples. It would be obvious to those skilled in the art that these examples are intended to be more concretely illustrative and the scope of the present invention as set forth in the appended claims is not limited to or by the examples.

EXAMPLES Example 1: Preparation of Plasmid DNA Expressing Isoforms of HGF

In order to carry out the following various experiments, the present inventors used the pCK vector as a vector capable of expressing isoforms of HGF. The pCK vector is constructed such that the expression of a subject to be expressed, e.g., an HGF gene, is regulated under enhancer/promoter of the human cytomegalovirus (HCMV), and is disclosed in detail in Lee et al., Biochem. Biophys. Res. Commun. 272:230 (2000); WO 2000/040737. Currently, the pCk vector is used for clinical trials on human body, and its safety and efficacy were confirmed (Henry et al., Gene Ther. 18:788 (2011)). In order to prepare plasmid DNAs expressing hybrid HGF genes as a therapeutic agent for diabetic neuropathy, the present inventors inserted each of the hybrid HGF genes into the pCK vector according to the method disclosed in U.S. Pat. No. 7,812,146.

Example 2: Verification of Hybrid HGF Genes Co-Expressing Isoforms of HGF

2-1. Construction of Vector Expressing Isoforms of HGF

In order to verify the expression of isoforms of HGF, gene expression vectors for cHGF (f1HGF), dHGF, and a hybrid form thereof were prepared, and the HGF gene expressing vector was compared with the cHGF or dHGF expressing vector. The cHGF obtained by treating the pCK-cHGF disclosed in U.S. Pat. No. 7,812,146 with BamHI was inserted into the BamHI site of the pVAX1 (Invitrogen, USA) to construct pVAX1-cHGF (FIG. 1). The HGF-X7 obtained by treating the pCP-HGF-X7 with Nhel and Apal was inserted into the pVAX1 treated with the same enzymes to construct pVAX1-HGF-X7 (FIG. 2).

The promoter obtained by treating the pVAX1-cHGF with NdeI and BstEII was inserted into the pCK-cHGF and pCK-dHGF without promoters, respectively, which were obtained by treatment with the same enzymes, to construct new plasmids, pCY-cHGF and pCY-dHGF, using the term pCY, respectively (FIG. 3). The pVAX1-HGF-X7 was treated with NdeI and BstEII to obtain a promoter, which was then inserted into the pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X7, and pCK-HGF-X8 without promoters, respectively, which were obtained by treatment with the same enzymes, to construct pCY-HGF-X3, pCY-HGF-X4, pCY-HGF-X7, and pCY-HGF-X8, respectively (FIG. 4). The pCY-HGF-X7 was treated with SpeI and BstEII to obtain a promoter, which was then inserted into the pCK-HGF-X2 and pCK-HGF-X6 without promoters, respectively, which were obtained by treatment with the same enzymes, to construct pCY-HGF-X2 and pCY-HGF-X6, respectively (FIG. 5). The pCY-HGF-X7 was treated with SnaBI and NheI to obtain a promoter, which was then inserted into the pCK-HGF-X5 without promoters, which was obtained by treatment with the same enzymes, to construct pCY-HGF-X5 (FIG. 6).

2-2. Verification of RNA Expression of Isoforms of HGF

Each of the plasmid DNAs was transfected into 1×10⁶ cells of 293T cells (ATCC CRL 1573) using FuGENE6 (Roche, USA) according to the manufacturer's instructions. At 48 hours after transfection, cells for each of the plasmids were harvested. RNA was extracted from the harvested 293T cells using the Trizol method (Trizol; Invitrogen, USA), and subjected to RT-PCR to obtain cDNA. PCR was conducted using the harvested cDNA as a template DNA and synthetic oligonucleotides of SEQ ID NO: 15 and SEQ ID NO: 16 as a primer pair. The PCR was conducted such that 3 μl of the template DNA, 1 μl each of 10 pmol/μl primer, 5 μl of 2.5 mM dNTP, 3.5 units of High fidelity enzyme mix (Roche, USA), and 5 μl of an enzyme buffer solution were mixed to prepare a total of 50 μl of a mixture liquid, which was then subjected to PCR amplification under conditions of 40 cycles of 30 seconds at 95°, 30 seconds at 60°, and 30 seconds at 72°. The thus amplified PCR products correspond to the boundary region between exon 4 and exon 5 of the HGF gene. Here, the nucleotide sequence of 142 bp is amplified for cHGF cDNA and the nucleotide sequence of 127 bp is amplified for dHGF cDNA.

As for the HGF-X gene, nucleotide sequences of at least 1 kb are amplified when the splicing does not occur, and both of the nucleotide sequences of 142 bp and 127 bp are amplified when alternative splicing occurs and thus cHGF and dHGF simultaneously are produced. The amplified PCR products were confirmed by electrophoresis on 15% polyacrylamide gels. As a result, the bands of 142 bp and 127 bp were detected for cHGF cDNA and dHGF cDNA, respectively, and both bands of 142 bp and 127 bp were detected for the hybrid HGF (FIG. 7).

2-3. Verification of Protein Expression of Isoforms of HGF

Each of the plasmid DNAs was transfected into 1×10⁶ cells of 293T cells (ATCC CRL 1573) using FuGENE6 (Roche, USA) according to the manufacturer's instructions. At 48 hours after transfection, the supernatant of each of the plasmid DNAs was harvested. The amount of HGF protein in the supernatant was measured using an enzyme-linked immunosorbent assay (ELIS; R&D System, MN, USA). As a result, it was verified that, among the hybrid HGF genes, HGF-X7 showed the highest protein expression level.

Example 3: Effect of Hybrid HGF Expressed in pCK Vector on Growth and Survival of Neuronal Cells

3-1. Effect of Hybrid HGF on Growth of Neuronal Cells

(1) Cell Line and Cell Culture

Rat-derived P12 pheochromocytoma (CRL-1721; ATCC, MD, USA) was used in this experiment. P12 cells are commonly used in the research of diabetic neuropathy. It has been recently validated that glucose reduces neuritis of PC12 cells (Fan Zhang et al., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 323:508-515 (2007)). In addition, it has been reported that glucose induces the reduction in proliferation of PC12 cells and DNA disruption, resulting in apoptosis of PC12 cells (EFRAT LELKES et al., Neurotoxicity research. 3:189-203 (2000)). PC12 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum and antibiotics under 37° and 5% CO₂. The cell culture medium, reagent, and serum were purchased from Gibco (Gibco BRL life technologies, inc., MD, USA), and plastic products for culture were purchased from BD Falcon (BD Falcon, NJ, USA).

(2) Preparation of Supernatants Containing Hybrid HGF Proteins and Recombinant Human HGF Protein

Supernatants expressing hybrid HGF proteins, that is, HGF-X2, HGF-X3, HGF-X4, HGF-X5, HGF-X6, HGF-X7, and HGF-X8 were produced using DNA transfection. The transfection was conducted by using the Cellphect phosphate calcium transfection system (GE Healthcare BioSciences, NJ, USA) according to the manufacture's protocol. 293T cell lines seeded at 1×10⁶ cells per well one day before were transfected with pCK, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7, and pCK-HGF-X8, and then the cells were incubated for 48 hours. Upon the completion of culturing, the supernatants were all harvested, and then filtered through a 0.22-μm filter. The harvested protein supernatants were frozen at −80° before use.

Recombinant human HGF protein was purchased from R&D (R&D Systems, Inc., MSP, USA) for use.

(3) Verification of Protein Expression and Protein Quantification

In order to verify the expression of the respective proteins in the supernatants of 293T cells, the human HGF immunoassay by R&D (R&D Systems, Inc., MSP, USA) was used. The expression levels of the respective proteins were measured, and then the respective supernatants were again diluted to 1 μg/ml for the use of experiments.

(4) Comparison of Cell Growth Among Hybrid HGF Proteins in PC12 Cells

In order to compare effects of hybrid HGF proteins on the growth of neuronal cells, the following experiment was conducted using PC12 cells. PC12 cells were seeded in a 6-well plate at 1×10⁵ cells per well, and the next day, the medium was exchanged with a medium containing 1% FBS. The 293T cell supernatant expressing each protein was added thereto at a concentration of 5 ng/ml, followed by culturing for 7 days, and then cell counting was conducted. As control groups, the supernatant of 293T cells transfected with the pCK vector and the recombinant human HGF protein were used. As a result, all the experiment groups added with the supernatants expressing all the hybrid HGF proteins excluding HGF-X4 were observed to exhibit higher cell growth than the control groups. The experiment groups added with the supernatants expressing HGF-X6, HGF-X7, and HGF-X8 showed statistically significant differences as compared with the control group (pCK vector) (P<0.05 or P<0.005; FIG. 9).

Since the pCK-HGF-X7 showed the highest gene expression level among the hybrid HGF genes (see, FIG. 8) and the distinctive statistical significance (P<0.005) in the growth of PC12 cells, the pCK-HGF-X7 was used in the following experiments and clinical trials.

3-2. Comparison Between Effects of HGF-X7 and cHGF on Growth of Neuronal Cells

(1) Cell Line and Cell Culture

Cell lines used in the present experiment were a total of two, PC12 cell line and human-derived SH-SY5Y neuroblasts (22266; KCLB, Korea). The SH-SY5Y cell line, like the PC12 cell line, is one of the most used cell lines for research of diabetic neuropathy. According to the study on diabetic neuropathy using SH-SY5Y cells, it has been known that glucose increases the depolarization of mitochondrial membranes of the SH-SY5Y cells and activates inactivated caspase-3, leading to apoptosis of the SH-SY5Y cells (G M Leinninger et al., Cell Death and Differentiation.11:885-896 (2004)). All the cells were cultured under conditions of 37° and 5% CO₂. The PC12 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum and antibiotics, and the SH-SY5Y cells were cultured in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum and antibiotics. The cell culture medium, reagent, and serum were purchased from Gibco and the ATCC (American Type Culture Collection, MD, USA).

(2) Production and Quantification of Supernatants Expressing HGF Proteins

293T cells were seeded at 1×10⁶ cells, and the next day, the cells were transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7. After culturing for 48 hours, the supernatants were all harvested, and then filtered through a 0.22-μm filter. The expression levels of the HGF proteins contained in the respective supernatants were measured using human HGF immunoassay. The respective supernatants were again diluted to 1 μg/ml for the use of experiments.

(3) Comparison Between Growths of PC12 Cells by HGF-X7 and cHGF

In order to compare effects on the growth of neuronal cells, the cell proliferation degrees by the respective proteins were evaluated using PC12 cells. For achieving this, PC12 cells were seeded in a 6-well plate at 1×10⁵ cells per well, and the next day, the medium was exchanged with a medium containing FBS. The respective proteins obtained from 293T cells transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7 were added thereto at concentrations of 5 ng/ml. The pCK vector was used for a control group.

As a result of cell counting after culturing for 7 days, the experiment group added with the supernatant of 293T cells containing HGF-X7 was verified to have the highest cell number. The experiment group added with HGF-X7 showed a cell growth effect, which was about 50% higher than that in cHGF and about 70% higher than that in dHGF (FIG. 10).

(4) Comparison Between Cell Growths of SH-SY5Y Cells by HGF-X7 and cHGF

In order to compare effects on the growth of neuronal cells, SH-SY5Y cells, the cell proliferation degrees by the respective proteins were measured. For achieving this, SH-SY5Y cell line was seeded in a 6-well plate at 5×10⁴ cells per well. The next day, the medium was exchanged with a medium containing 1% FBS. The respective proteins obtained from 293T cells transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7 were added thereto at concentrations of 5 ng/ml. The pCK vector was used for a control group.

As a result of cell counting after culturing for 7 days, the experiment group added with the supernatant of 293T cells containing HGF-X7 was verified to have the highest cell number. The experiment group added with HGF-X7 showed a cell growth effect, which was about 25% higher than that in cHGF and about 80% higher than that in dHGF (FIG. 11).

3-3. Effect of HGF-X7 on Growth of PC12 Cells in Culture Conditions of High-Concentration Glucose

(1) Selection of Glucose Concentration and Culture Time for Inhibition of Growth of PC12 Cells

Prior to the verification of an effect of HGF-X7 on the growth of PC12 cells under the culture conditions of high-concentration glucose, the glucose concentration and the culture time for inhibiting the growth of PC12 cells were selected. PC12 cells were seeded in a 96-well plate at 5×10⁴ cells per well, and the next day, the medium was exchanged with 100 mM and 200 mM glucose media containing 1% FBS, respectively. As a control group, a medium containing 50 mM glucose, which was a culture medium of PC12 cells, was used. At 24, 48, and 72 hours after medium exchange, the cell growth was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, WI, USA). The growth of PC12 cells was verified to be reduced in the high-concentration glucose medium. In particular, the growth of PC12 cells was observed to be reduced by about 50% in the 200 mM glucose medium at 48 hours and 72 hours. Based on these results, the glucose concentration and the culture time for inhibiting the growth of PC12 cells were selected to be 200 mM and 72 hours, respectively.

(2) Verification of Effect of HGF-X7 on Growth of PC12 Cells in Culture Conditions of High-Concentration Glucose

The effect of HGF-X7 on the growth of PC12 cells in the culture conditions of high-concentration glucose was confirmed. PC12 cell line was seeded in a 96-well plate at 5×10⁴ cells per well. The next day, the medium was exchanged with a 200 mM glucose medium, and then 50 ng/ml of the 293T cell supernatant expressing HGF-X7 was added thereto.

As a result of confirming the cell growth after culturing for 72 hours, it was observed that the experiment group added with the supernatant expressing HGF-X7 showed an increase by about 23% or more in cell growth as compared with the control group (pCK vector), and an increase by about 10% or more in cell growth as compared with the experiment group added with the same concentration of the supernatant containing cHGF.

3-4. Effect of HGF-X7 on Apoptosis Inhibitory Effect of PC12 Cells Under the Culture Conditions of High-Concentration Glucose

(1) Selection of Glucose Concentration and Culturing Time for Inducing Apoptosis of PC12 Cells

Prior to the estimation of an effect of HGF-X7 on apoptosis of PC12 cells under the culture conditions of high-concentration glucose, the glucose concentration and the culture time for inducing apoptosis of PC12 cells were selected. The PC12 cell line was seeded in a 6-well plate at 1×10⁵ cells per well, and the next day, the medium for the PC12 cell line was exchanged with 50 mM, 100, mM, and 200 mM glucose media containing 1% FBS. The cells were cultured for 48 hours or 72 hours, and then all the cells were collected. The supernatants were removed by centrifugation for 3 minutes at 12000 rpm, followed by washing with PBS. This procedure was repeated once more. The degrees of apoptosis for the collected cells were measured using the Annexin V apoptosis assay system (BD Biosciences, NJ, USA). A 1× Annexin V binding buffer was put into the collected cells at a volume of 1 ml per 1×10⁶ cells, so that the cells were suspended in the buffer. 5 μl of Annexin-V and a propidium iodide buffer were added to 100 μl of the suspended cells to stain the suspended cells for 20 minutes in the dark. 400 μl of a 1× Annexin V binding buffer was further added to the stained cells to detect apoptosis by flow cytometry.

As a result, the apoptosis of PC12 cells was not induced when the cells were cultured in the 100 mM glucose medium for 48 hours, as compared with the control group, but about 2.5-fold of apoptosis was induced in the 200 mM glucose medium as compared with the control group. Whereas, it was verified that, under the culture conditions for 72 hours, the apoptosis was induced in both 100 mM and 200 mM glucose media as compared with the control group, and the significant difference between 100 mM and 200 mM glucose media was not shown. Based on these results, the glucose concentration and the culture time for inducing apoptosis of PC12 cells were selected to be 200 mM and 48 hr, respectively.

(2) Effect of HGF-X7 on Apoptosis of PC12 Cells in Culture Conditions of High-Concentration Glucose

The PC12 cell line was seeded in a 6-well plate at seeded in at 1×10⁵ cells per well, and the next day, the medium for the PC12 cell line was exchanged with 200 mM glucose medium containing 1% FBS. 50 ng/10 of the 293T cell supernatant expressing cHGF or HGF-X7 was added thereto. As a control group, the supernatant of 293T cells transfected with the pCK vector was used. After culturing for 48 hours, all the cells were collected. Staining was conducted using the Annexin V apoptosis assay system, and then the degrees of apoptosis were confirmed by flow cytometry.

As a result, the experiment group added with the 293T cell supernatant expressing HGF-X7 was verified to lead to a 2-fold decrease in apoptosis as compared with the control group added with the 293T cell supernatant expressing the pCK vector and show an apoptosis inhibitory effect of about 1.5 times or higher as compared with the experiment group added with the supernatant containing cHGF (FIG. 13).

Example 4: Clinical Trial of pCK-HGF-X7 Against Diabetic Neuropathy

4-1. Subjects and Administration

A phase I clinical trial for safety and efficacy of pCK-HGF-X7 was conducted for 12 patients diagnosed with diabetic neuropathy. The time and dose of administration were different for three trial groups as shown in Table 1.

TABLE 1 Number of times Trial Dose of of administration Total dose of group administration Day 0 Day 14 administration I 4 mg 8 8  8 m 

II 8 mg 16 16 16 m 

III 16 mg  32 32 32 m 

4-2. Methods

(1) Informed Consent Form and Screening Procedure

After receiving informed consent forms from patients, a screening procedure for checking the possibility of participating in the present clinical trial was conducted. The screening procedure was conducted within 30 days before day 0 of primary administration, and the possibility of participating in the present clinical trial was determined for each of the patients based on the following items.

a. complete medical history

b. complete physical exam

c. cancer screening tests

d. retinal fundoscopy

e. viral screening tests

f. hematology and serum chemistry

g. urinalysis

h. urine pregnancy test (for only females)

i. Ulcer screening (if possible)

j. ECG

k. Michigan Neuropathy Screening Instrument

l. Visual Analogue Scale

(2) Administration of Trial Drug

The pCK-HGF-X7 was injected in the right calf muscle of each of the subjects undergoing screening at an interval of two weeks (Day 0 and Day 14). The subjects assigned to trial group I were administered with 2 mg of pCK-HGF-X7 on Day 0, and again administered with 2 mg of pCK-HGF-X7 on Day 14. Therefore, trial group I was administered with a total of 4 mg of pCK-HGF-X7. On Day 0, each of the subjects was administered with 2 mg of pCK-HGF-X7, which was injected in eight sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the administration was also conducted in the same manner. Trial group II was administered with a total of 8 mg of pCK-HGF-X7 (4 mg on Day 0 and 4 mg on Day 14). The administration was conducted similarly to trial group I. That is, on Day 0, each of the subjects of trial group II was administered with 4 mg of pCK-HGF-X7, which was injected in 16 sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the administration was conducted in the same manner. Trial group III was administered with a total of 16 mg of pCK-HGF-X7 (8 mg on Day 0 and 8 mg on Day 14). On Day 0, each of the subjects of trial group III was administered with 8 mg of pCK-HGF-X7, which was injected in 32 sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the injection in 32 sites was conducted in the same manner.

4-3. Clinical Evaluation Indicator

The primary endpoint of the present clinical trial is to confirm the safety of pCK-HGF-X7 injected in the calf muscle of each of the patients with diabetic neuropathy, and the secondary endpoint of the present clinical trial is to confirm the efficacy of pCK-HGF-X7 on pain, which is a main symptom of diabetic neuropathy.

(1) Safety Analysis

All the subjects administered with the trial drug in the present clinical trial are to be tested for safety analysis. Through follow-up observation of 12 months after administration, adverse event data (including adverse events and adverse events to stop administration of trial drug) were all recorded according to the extents thereof and relations with the trial drug. If possible, safety analysis was conducted through all statistical analysis. In addition, in order to avoid risks associated with cancers, all the subjects were screened by the method specified in the American Cancer Society Cancer Screening Guideline during the screening procedure.

(2) Pharmacokinetic Analysis

The level of HGF protein in serum of the subject and the amount of pCK-HGF-X7 in blood of the subject were measured before and after the administration of the trial drug of Day 0, and before and after the administration of the trial drug of Day 14, on Day 21, on Day 30, on Day 60, and on Day 90.

(3) Efficacy Analysis

A visual analogue scale (VAS) method was used to record the change in pain for all the subjects. According to the VAS method, the individual preference for a health state was directly measured. That is, each of the subjects is allowed to directly score a scale for the severity of pain. A 100 mm-long line was drawn, and “No pain at all” was marked at one side of the line and “Pain as bad as it can be” was marked at the other side of the line. Then, the subjects are allowed to determine and record the severity of pain by themselves according to the VAS indicator. This method cannot show the comparison between different subjects, but can show the change in the severity of pain for the same subject (FIG. 14). In order to deduce clinically significant results, the safety analysis was conducted through every possible statistical analysis.

4-4. Results

(1) Safety Results (Adverse Event Report)

As for the adverse events due to administration of pCK-HGF-X7 of the present invention, seven adverse events occurred in a total of three subjects of trial group I; two adverse events occurred in two subjects of trial group II; and two adverse events occurred in two subjects of trial group III. The adverse events were reported to be dry eyes, injection site pain, dry mouth, diarrhea, and the like in trial group I; back pain and sinusitis in trial group II; and right rib pain and viral syndrome in trial group III. The number of adverse drug events was five, which were reported in two subjects of trial group I, dry eyes (two events), injection site pain, dry mouth, and diarrhea, but they correspond to mild adverse drug events and thus recovered soon. Whereas, no serious adverse events were reported.

(2) Pharmacodynamics (PD) Results

As a result of confirming the amount of HGF protein produced in serum after administration of pCK-HGF-X7, it was verified that the level of HGF protein in serum after administration of pCK-HGF-X7 was not increased but maintained during the clinical trial (FIG. 15).

(3) Pharmacokinetics (PK) Results

As a result of confirming the amount of pCK-HGF-X7 remaining after pCK-HGF-X7 treatment, the pCK-HGF-X7 DNA was not detected in ten subjects during follow-up observation of 60 days, and was detected at under 100 copies/ml for all the subjects (Table 2).

TABLE 2 Day 0 Day 14 Trial Patient Prior Post Prior Post Day Day Day Day group ID administration administration administration administration 21 30 60 90 I 1-01 NEG 45846.3 NEG 62,762.8 10.0 7.1 NEG NEG 2-01 NEG 38401.5 NEG 18,215.9 NEG NEG NEG NEG 2-02 NEG 5871.8 NEG 38,401.5 NEG NEG NEG NEG 2-03 NEG 18215.9 NEG 5,871.8 NEG NEG NEG NEG II 2-04 NEG 562,669.0 NEG 300,852.0 51.0 NEG 38.1 NEG 1-02 NEG 114,319.0 333.0 139,297.0 56,266.9 219.0 91.1 NEG 2-05 NEG 183,514.0 63.0 582,978.0 3,875.0 69.0 NEG 28.9 1-03 5.1 177,131.0 319.0 1,532,729.0 262.8 108.1 NEG NEG III 1-04 NEG 1,920,770.8 148 6,252,606.8 1,637.5 162.2 NEG 42.7 2-07 NEG 368,173.0 NEG 23,198.3 32.9 NEG NEG NEG 2-08 NEG 76,888.4 170.7 101,424.0 157.6 58.6 50.6 NEG 2-09 NEG 491,690.2 77.1 432,454.6 77.6 33.7 NEG NEG

(4) Efficacy Test Results

The severity of pain was measured through the Pain VAS (Visual Analogue Scale). As for a total of twelve subjects, the mean baseline VAS value was 48.0, and the mean VAS value at six months after the pCK-HGF-X7 treatment was 25.4, which showed a 47% reduction in the pain VAS value (FIG. 16).

In the case of the first dose group (4 mg), the mean baseline VAS value was 39.5, and the mean VAS value at two months after treatment was 23.8, which showed a 39.7% reduction in the pain VAS value, but the mean VAS value at six months after treatment was 31.3, which merely showed a 20.8% reduction in the pain VAS value as compared with the baseline value. In the first dose group, the pain reduction was observed in three of four subjects and the pain reduction of 50% or higher was observed in two of four subjects (FIG. 17).

In the case of the second dose group (8 mg), the mean baseline VAS value was 59.1, and the VAS value from one month after treatment was sharply reduced and the mean VAS value at six months after treatment was 27.5, which showed a 53.5% reduction in the pain VAS value as compared with the baseline value (FIG. 18).

In the case of the third dose group (16 mg), the mean baseline VAS value was 45.3. Similarly to the second dose group, the VAS value from one month after treatment was sharply reduced and the mean VAS value at six months after treatment was 17.3, which showed a 61.4% reduction in the pain VAS value as compared with the baseline value. In the third dose group, the pain reduction was observed in all four subjects and the pain reduction of 50% or higher was observed in three of four subjects (FIG. 19).

As a result of surveying the efficacy using the pain VAS, the pain, which is the main symptom of diabetic neuropathy, was reduced after the pCK-HGF-X7 injection, and the pain reduction rate and the response rate to pain reduction were more remarkable in the medium-dose group (8 mg) or the high-dose group (16 mg) than in the low-dose group (4 mg). These results supported that the pain reduction observed in the present clinical trial was due to the administration of pCK-HGF-X7 and not the placebo effect (FIG. 20).

Having described a preferred embodiment of the present invention, it is to be understood that variants and modifications thereof falling within the spirit of the invention may become apparent to those skilled in this art, and the scope of this invention is to be determined by appended claims and their equivalents. 

1. A pharmaceutical composition for the prevention or treatment of diabetic neuropathy, the composition comprising, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms. 